StockWatch
·
SOLAR INDUSTRIES INDIA LTD. · QQ2 FY-2027 · THE CALL

Record growth, guidance beat track solid—defense upside requires years

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsSOLARINDSSOLAR INDUSTRIES INDIA LTD.06 Nov 2026 · 6 min read
Verdict

Buy

confidence 8/10

Credibility

Grade A

Hit FY27 interim targets, confident on beat, clear on near-term. No prior misses flagged.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Q2 delivered 69% YoY growth and 80% PAT growth with margin expansion (29% EBITDA), on track to beat ₹14,000 Cr FY27 guidance. Large order book (₹20,178 Cr) and structural defense opportunity (Pinaka, Bhargavastra) underpin long-term. Key risk: major defense programs are 2–3 years to commercialization; external headwinds (commodity, supply chain) could compress margins.

₹3518.9 Cr

Revenue · +69% YoY

₹650 Cr

Reported PAT · +79.7% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Domestic explosives stand at 29%, up from 27%

MET

Domestic mix 29% vs 27% prior year—exact call figures

International explosives 43%, down from 46% YoY

MET

International 43% vs 46% prior year—call exact

Defense revenue 29% of mix, up from 24%

MET

Defense ₹1,002 Cr = 29% of ₹3,519 Cr Q2; prior year 24%

Will surpass ₹14,000 Cr FY27 guidance

MET

H1 ₹7,187 Cr on track; Q2 monsoon-impacted (-4.1% QoQ), H2 expected stronger; pace supports beat

Margins to reach 28–30%, expecting ~29% FY27

MET

H1 EBITDA margin 28.45%, Q2 at 29.02%; full-year ~29% is realistic vs 28% prior guidance

Earnings quality

What changed since the last call

Deltas vs. the prior call

Defense revenue mix expanded

Upgrade

Defense now 29% of revenue (₹1,002 Cr Q2) vs 24% prior year; tracking to ₹4,500 Cr FY27 on path

FY27 margin outlook raised modestly

Upgrade

Expecting 28–30% (avg ~29%) vs prior 28% guidance; H1 EBITDA margin 28.45%, Q2 at 29.02%

International 43%, domestic recovered

Neutral

International 43% (vs 46% prior, -300 bps) but domestic 29% (vs 27%, +200 bps); domestic demand pickup compensated

No FY28/29 guidance quantified

Withdrawn

Management explicitly said will provide multi-year targets only after FY27 close; deferred clarity

The Q&A

Analysts probed defense timelines, Omnia integration, MALE UAV status, margin sustainability, capacity constraints. Management candid on trials (Pinaka/Bhargavastra 2–3 years to commercialization), deferred Omnia updates, acknowledged MALE UAV news drought but stayed confident on execution. Held firm on ₹14,000 Cr beat.

The exchanges that mattered

Domestic non-defense growth — Amit Dixit, Goldman Sachs

Answered

Growth momentum will be better in H2. Monsoon impact Q2; coal mining demand good. Expect strong domestic growth H2 also. Demand outlook positive.

Pinaka order status — Amit Dixit, Goldman Sachs

Answered

Pinaka order ~₹3,000 Cr expected, negotiation ongoing. Received bid ~1.5 years back. In final negotiation stage now. Order book given best price, expect conclusion very soon.

155mm shells capacity — Amit Anwani, PL Capital

Answered

Establishing 155mm facility, set up already. Want to scale up to 155mm vertical. Established counter-drone systems in Indian market, will help break international orders. Pinaka supplies ongoing.

Missile tech/MALE UAV — Vikash Singh, ICICI Securities

Answered

Missile tech opportunity aligned with Solar's capabilities (energetic materials, propellants, warheads, rocket integration). One of most competent private partners for tactical missile programs. MALE UAV: news dried up; no current procurement impact.

Defense capability gaps — Amit Mahawar, UBS Securities

Answered

Defense complex; in it 15 years. Always challenging to adopt new technologies. At Solar, integrated large facilities handling all ammunition types. Focusing on developing programs with DRDO. Continuous process finding gaps. Confident should adopt new things, offer smart products.

FY27 guidance beat & margins — Tanmay, Aditya Birla Sun Life

Answered

Will definitely surpass ₹14,000 Cr FY27 guidance. H1 always weaker, H2 better. Domestic now 27–28%, will deliver more H2. Margins will cross 29% on average. Defense at ₹1,000 Cr Q2, ₹900 Cr prior Q = ₹1,900–₹2,000 Cr H1 total; expect ₹4,500 Cr FY27. Surpass guidance on top line.

Bhargavastra trials timeline — Pinakin, HSBC

Answered

Bhargavastra: like said, internal trials calendar year and field trial also calendar year. Once complete, commercialization starts. Years to reach commercialization stage. Huge demand for such products.

Omnia acquisition clarity — Pinakin, HSBC

Partial

Omnia detailed call couple months back, no more updates at this stage. Questions can be answered once acquisition is completed.

155mm shells delivery timelines — Kavish Parekh, 360 ONE Capital

Partial

Share at appropriate stage on 155mm program. Total order book defense ~₹18,000 Cr, most from international markets. Will address 155mm program at right time. Variety of products in order book including 155mm products.

Volume growth outlook & capex — Kavish Parekh, 360 ONE Capital

Answered

Capacity expansion in different parts of country for growing domestic demand, especially housing/infrastructure/coal mining. Industry growth ~6–7%, our volume growth 10–15% range. Will be enhanced by capability & capacity expansion.

Defense/export business outlook — Amit Mahawar, UBS Securities

Dodged

This call is for quarterly/half-yearly results. Will provide full clarity on FY27 results. Cannot give guidance for FY28/29 yet due to uncertainties (geopolitical, supply chain, commodity). Will restrict discussion to Q2 H1 FY27 results.

International order book detail — Tanmay, Aditya Birla Sun Life

Partial

Supply to 90+ countries. Inquiries practically from every nation allowed by Government of India. 20,178 Cr order book, defense ~₹17,568 Cr. Getting inquiries & orders from various countries. Cannot disclose details per confidentiality.

Guidance

Forward guidance and management's confidence

FY27: ₹14,000 Cr+ (will 'surpass' baseline target)

High

H1 ₹7,187 Cr on pace. Q2 monsoon-impacted (-4.1% QoQ); H2 seasonally stronger. Beat implied by management.

FY27: 28–30% EBITDA margin, expecting ~29% avg

High

H1 EBITDA margin 28.45%, Q2 at 29.02%. Prior target 28%; upside now 28–30%. Defense upside to benefit margins.

Greenfield expansion ongoing; no specific FY27 capex target disclosed

Medium

Prior FY27 guidance was ₹2,050 Cr capex. Expansion in domestic capacity (155mm shells facility, ammunition lines) underway.

Risks the call surfaced

Ranked by how much they should concern a holder

Defense program execution

High

Pinaka (₹3,000 Cr expected) and Bhargavastra (₹3,000+ Cr) still in trial phase. Commercialization 2–3 years out. RFP conversion uncertain; contract finalization can take years.

Commodity & supply chain

Medium

Geopolitical issues, supply chain disruptions, commodity price volatility acknowledged. Could compress EBITDA margins (target 28–30%) if unabated.

International market exposure

Medium

International explosives 43% of revenue; 90+ countries served but specifics withheld for confidentiality. Exports subject to GOI restrictions. Geopolitical shifts could limit market access.

Domestic market cyclicality

Medium

Domestic explosives 29% of revenue; demand tied to coal mining, infrastructure investment. Monsoon impact Q2 evident (-4.1% QoQ). Slowdown could compress H2 growth.

Omnia acquisition

Low

Omnia (agri-explosives) acquisition pending approvals. No updates provided; contingent on regulatory/antitrust clearance. Delays could defer accretive revenue.

Management

Score 8/10. Clear on Q2 numbers and segment splits. Candid on defense program timelines (2–3 years to commercialization). Deferred FY28/29 guidance citing uncertainty—prudent, not evasive. Q2 beat FY27 interim targets (revenue ₹3,519 Cr on guidance), margins 29% (vs 28% prior). H1 on pace to beat ₹14,000 Cr FY27. No material misses flagged.

What to watch next
  • 1 · H2 FY27

    Seasonal demand recovery (monsoon over), higher revenue expected vs Q2; on track for ₹14,000+ Cr beat

  • 2 · FY28–FY29

    Defense program commercialization (Pinaka, Bhargavastra); RFP flow expected post trials

  • 3 · CY2026–2027

    Omnia acquisition close (pending approvals); agri-explosives portfolio addition

Key risk: major defense programs are 2–3 years to commercialization; external headwinds (commodity, supply chain) could compress margins.

Informational and educational content only. Not investment advice.